DORSET MEDICINES ADVISORY GROUP

COMMISSIONING STATEMENT ON THE USE OF TOLVAPTAN FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (TA358)

SUMMARY

NHS Dorset Clinical Commissioning Group commissions the use of Tolvaptan (Jinarc®) as an option for treating autosomal dominant polycystic kidney disease in adults to slow progression of cyst development and renal insufficiency where patients have chronic kidney disease stage 2 or 3 at the start of treatment and there is evidence of rapidly progressing disease, in accordance with NICE TA339.

BACKGROUND	Tolvaptan (Jinarc®, Otsuka Pharmaceuticals UK) is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. It is a selective vasopressin antagonist which inhibits the binding of vasopressin to the V2 receptors, therefore reducing cell proliferation, cyst formation and fluid excretion. Tolvaptan is to be administered twice daily in split dose regimens of 45 mg + 15 mg, 60 mg + 30 mg or 90 mg + 30 mg. The morning dose is to be taken at least 30 minutes before the morning meal. The second daily dose can be taken with or without food. According to these split dose regimens the total daily doses are 60, 90, or 120 mg. Tolvaptan treatment must be initiated and monitored under the supervision of physicians with expertise in managing ADPKD and a full understanding of the risks of tolvaptan therapy including hepatic toxicity and monitoring requirements. People who take tolvaptan need to drink significantly more water than people not taking tolvaptan. Patient experts on the NICE appraisal group reported that this lifestyle change was manageable, with some planning.
RELEVANT NICE GUIDANCE	NICE TA358 states: Tolvaptan is recommended as an option for treating autosomal dominant polycystic kidney disease in adults to slow the progression of cyst development and renal insufficiency only if: • they have chronic kidney disease stage 2 or 3 at the start of treatment • there is evidence of rapidly progressing disease and • the company provides it with the discount agreed in the patient access scheme.
FORMULARY STATUS	Red, specialist use only
PBR STATUS	Excluded from tariff

<table>
<tr><td>COMMISSIONING IMPLICATIONS</td><td>Dorset CCG are the responsible commissioners for tolvaptan for the indication detailed in TA358 whilst NHS England are responsible for the use of tolvaptan when used in hyponatraemia in lung cancer (although it is not routinely commissioned by them for this indication with individual funding approval requiring to be sought).</td></tr>
<tr><td>RELEVANT CLINICAL WORKING GROUP</td><td>Planned and specialist</td></tr>
<tr><td>PATIENT PATHWAY IMPLICATIONS</td><td>This is the first treatment for people with autosomal dominant polycystic kidney disease that targets the disease and delays progression in terms of both total kidney volume growth and rate of kidney function decline. It is anticipated that tolvaptan is likely to be an additional cost of treating people with autosomal dominant polycystic kidney disease. However there may be future savings from avoided hospital admissions due to improved management. There may also be a delayed need to dialysis or kidney transplant.</td></tr>
<tr><td>SUMMARY OF EVIDENCE TO SUPPORT FORMULARY STATUS</td><td>Summarised in ‘consideration of the evidence’ section of TA358

The summary of product characteristics lists the following adverse reactions for tolvaptan: thirst, polyuria, nocturia, pollakiuria (frequent urination), serum alanine aminotransferase or aspartate aminotransferase elevation. Hepatotoxicity has been observed in some people having tolvaptan for autosomal dominant polycystic kidney disease.</td></tr>
<tr><td>ASSESSMENT OF COST IMPLICATIONS</td><td>NICE states: “Tolvaptan is available as 15 mg, 30 mg, 60 mg and 90 mg tablets, in 28-day packs of split-dose tablets, at a flat net price of £1208.20, equating to £43.15 per day, regardless of dose. The company provided these costs to NICE because the British National Formulary (BNF) had not listed the price at the time of producing this guidance. The annual cost of tolvaptan is estimated by the company to be £15,750 per person. The company has agreed a patient access scheme with the Department of Health. This scheme provides a simple discount to the list price of tolvaptan, with the discount applied at the point of purchase or invoice. The level of the discount is commercial in confidence.”

The NICE costing statement suggests that 4 patients per 100,000 might require this treatment. This would equate to approximately 24 adult patients in Dorset. The costing statement suggests slow uptake initially, with the following predictions for five financial years.

<table>
<tr><th>description</th><th>current</th><th>2015/16</th><th>2016/17</th><th>2017/18</th><th>2018/19</th><th>2019/20</th></tr>
<tr><td>Estimated uptake</td><td>1%</td><td>1.67%</td><td>6%</td><td>13.5%</td><td>30%</td><td>50%</td></tr>
<tr><td>Dorset patients taking tolvaptan</td><td>0</td><td>0</td><td>1</td><td>3</td><td>7</td><td>12</td></tr>
</table>
</td></tr>
</table>

REFERENCES	NICE TA 354 Tolvaptan for treating autosomal dominant polycystic kidney disease. Summary of product characteristics. Tolvaptan, Jinarc® Otsuka Pharmaceuticals UK, accessed 22 December 2015
Date	December 2015
Review date	December 2017 or before in the light of new information
Contact	Michelle Trevett, Senior Pharmacist, NHS Dorset CCG